Lindawati Rahayu
ABSTRACT
Substandard and falsified drugs becomes a major problem around the world for years. Despite many cases occurred and cause not only huge financial loss but some cases reported with mortality, the existence of substandard and falsified drugs continuing and increasing rampantly. As an essential substance in human lives, these problems need the greatest attention and collaboration among parties to address the issue. This paper maps the problems through many sources and using a system dynamics approach to generate a structural model of variables in the drugs ecosystem. In the later stage, the model will be simulated under various scenarios to seek policy options in substandard and falsified drugs matters.
- Dora Akunyili. 2004. Fake And Counterfeit Drugs In The Health Sector: The Role Of Medical Doctors. 2: 19--23.Google Scholar
- Sławomir Wilczyński, Robert Koprowski, Mathieu Marmion, Piotr Duda, and Barbara Blońska-Fajfrowska. 2016. The use of hyperspectral imaging in the VNIR (400-1000 nm) and SWIR range (1000-2500 nm) for detecting counterfeit drugs with identical API composition. Talanta 160: 1--8. https://doi.org/10.1016/j.talanta.2016.06.057Google ScholarCross Ref
- Elizabeth Pisani. 2017. WHO Global Surveillance and Monitoring System. Geneva. Retrieved from https://www.who.int/medicines/regulation/ssffc/publications/gsms-reportsf/en/Google Scholar
- Roger Bate, Ginger Zhe Jin, and Aparna Mathur. 2015. Falsified or Substandard: Assessing Price and Non-price Signals of Drug Quality. Journal of Economics and Management Strategy 24, 4: 687--711. https://doi.org/10.1111/jems.12114Google ScholarCross Ref
- Sanjay Bhushan. 2017. System dynamics modelling-based analysis of combating counterfeit drugs supply chain in India. International Journal of Emergency Management 13, 1: 19--49. https://doi.org/10.1504/IJEM.2017.081191Google ScholarCross Ref
- Gillian J Buckley and Lawrence O Gostin. 2013. Causes of Falsified and Substandard Drugs. In Countering the problem of falsified and substandard drugs. National Academy of Sciences, United States of America, 137--176Google Scholar
- Atholl Johnston and David W. Holt. 2014. Substandard drugs: A potential crisis for public health. British Journal of Clinical Pharmacology 78, 2: 218--243. https://doi.org/10.1111/bcp.12298Google ScholarCross Ref
- Tariq Almuzaini, Imti Choonara, and Helen Sammons. 2013. Substandard and counterfeit medicines: A systematic review of the literature. BMJ Open 3, 8: 1--7. https://doi.org/10.1136/bmjopen-2013-002923Google ScholarCross Ref
- Gaurvika M.L. Nayyar, Joel G. Breman, Tim K. Mackey, John P. Clark, Mustapha Hajjou, Megan Littrell, and James E. Herrington. 2019. Falsified and substandard drugs: Stopping the pandemic. American Journal of Tropical Medicine and Hygiene 100, 5: 1058--1065. https://doi.org/10.4269/ajtmh.18-0981Google ScholarCross Ref
- WHO. 2017. A Study on the Public Health and Socioeconomic Impact. Geneva. Retrieved from https://www.who.int/medicines/regulation/ssffc/publications/se-study-sf/en/Google Scholar
- Interpol. 2019. Operation Pangea - shining a light on pharmaceutical crime. November 2019: 1--10. Retrieved from https://www.interpol.int/en/News-and-Events/News/2019/Operation-Pangea-shining-a-light-on-pharmaceutical-crimeGoogle Scholar
- Eric Przyswa. 2013. Counterfeit, Medicines and Criminal Organisations. International Institute of Research Against Counterfeit Medicines, September 2013: 1--126. https://doi.org/10.2139/ssrn.1725072Google Scholar
- Bagozzi Daniela and Christian Lindmeier. 2017. 1 in 10 medical products in developing countries is substandard or falsified. Retrieved December 3, 2019, from https://www.who.int/news-room/detail/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsifiedGoogle Scholar
- Tariq Almuzaini, Helen Sammons, and Imti Choonara. 2013. Substandard and falsified medicines in the UK: A retrospective review of drug alerts (2001-2011). BMJ Open 3, 7. https://doi.org/10.1136/bmjopen-2013-002924Google ScholarCross Ref
- Naira Ghanem. 2019. Substandard and falsified medicines: Global and local efforts to address a growing problem. Clinical Pharmacist 11, 5: 1--11. https://doi.org/10.1211/CP.2019.20206309Google Scholar
- Peter B. Checkland and Michael G. Haynes. 2019. Varieties of systems thinking: The case of soft systems methodology. Management Control Theory 3, January: 151--159Google Scholar
- Sachiko Ozawa, Daniel R. Evans, Colleen R. Higgins, Sarah K. Laing, and Phyllis Awor. 2019. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study. Malaria Journal 18, 1: 1--14. https://doi.org/10.1186/s12936-018-2628-3Google ScholarCross Ref
- Sachiko Ozawa, Deson G. Haynie, Sophia Bessias, Sarah K. Laing, Emery Ladi Ngamasana, Tatenda T. Yemeke, and Daniel R. Evans. 2019. Modeling the economic impact of substandard and falsified antimalarials in the Democratic Republic of the Congo. American Journal of Tropical Medicine and Hygiene 100, 5: 1149--1157. https://doi.org/10.4269/ajtmh.18-0334Google ScholarCross Ref
- Amani Thomas Mori, Estella Meena, and Eliangiringa A. Kaale. 2018. Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: A retrospective review of data from the regulatory authority. BMJ Open 8, 6: 1 -7. https://doi.org/10.1136/bmjopen-2018-021825.Google ScholarCross Ref
- John. D. Sterman. 2000. Sterman-Business Dynamics - 3.pdf.Google Scholar
- Warren E. Walker and C. Els van Daalen. 2013. System Models for Policy Analysis. In Public Policy Analysis: New Developments. 157--184. https://doi.org/10.1007/978-1-4614-4602-6_7Google Scholar
- T. E. Van Der Lei, B. Enserink, W. A.H. Thissen, and G. Bekebrede. 2011. How to use a systems diagram to analyse and structure complex problems for policy issue papers. Journal of the Operational Research Society 62, 7: 1391 -1402. https://doi.org/10.1057/jors.2010.28Google ScholarCross Ref
- Hamid Ghodse. 2008. Counterfeit medicines and the unregulated market for drugs. International Psychiatry 5, 3: 53--54. https://doi.org/10.1192/s1749367600002034Google ScholarCross Ref
- Andrew O'Hagan and April Garlington. 2018. Counterfeit drugs and the online pharmaceutical trade, a threat to public safety. Foresic Research & Criminology International Journal 6, 3: 151--158. https://doi.org/10.15406/frcij.2018.06.00200Google Scholar
Index Terms
- Conceptual Model of Substandard and Falsified in Ddrugs System
Recommendations
Conceptual Model of Analysing Risk in a Fuel Gas Supply System (FGSS) on LNG Fuelled-gas Vessel
APCORISE '20: Proceedings of the 3rd Asia Pacific Conference on Research in Industrial and Systems EngineeringThis study aims to propose a risk analysis framework using the FMEA method and system dynamics approach. FMEA is used as a first stage to identify critical equipment/ system based on the highest RPN, then uses the value of the O (Occurrence) as an input ...
System Dynamics Approach to Malicious Insider Cyber-Threat Modelling and Analysis
Human Aspects of Information Security, Privacy and TrustAbstractEnforcing cybersecurity controls against malicious insiders touches upon complex issues like people, process and technology. In large and complex systems, addressing the problem of insider cyber threat involves diverse solutions like compliance, ...
A multi-level approach to understanding the impact of cyber crime on the financial sector
This paper puts forward a multi-level model, based on system dynamics methodology, to understand the impact of cyber crime on the financial sector. Consistent with recent findings, our results show that strong dynamic relationships, amongst tangible and ...
Comments